Work

Primary analysis of the randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high-risk multiple myeloma (SWOG-1211).

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.8507

Authors: Saad Zafar Usmani, Sikander Ailawadhi, Rachael Sexton, Antje Hoering, Brea Lipe, Sandi Hita, Brian G. Durie, Jeffrey A. Zonder, Madhav V. Dhodapkar, Natalie Scott Callander, S. Vincent Rajkumar, Peter Michael Voorhees, Paul G. Richardson, Robert Z. Orlowski

Institutions: Levine Cancer Institute, Mayo Clinic in Florida, Cancer Research And Biostatistics, University of Rochester, Cedars-Sinai Medical Center, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Yale University, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Mayo Clinic, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Institutes of Health

OpenAlex ID: W3028908409

Cites:

Cited by: 26

Related to: 10